MedTrace Logo

Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

NCT06616571 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2024-09-27

No results posted yet for this study

Summary

The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.

Conditions

  • Chemotherapy-Induced Febrile Neutropenia

Interventions

DRUG

QL0605(PEG-rhG-CSF)

Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.

DRUG

QL0605(PEG-rhG-CSF)

Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-19
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06616571 on ClinicalTrials.gov